# Phase 1 ALKS 1140 in Healthy Adults

> **NCT05019105** · PHASE1 · TERMINATED · sponsor: **Alkermes, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Central Nervous System Diseases

## Interventions

- **DRUG:** Placebo
- **DRUG:** ALKS 1140

## Key facts

- **NCT ID:** NCT05019105
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-13
- **Primary completion:** 2022-08-23
- **Final completion:** 2022-08-23
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2022-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05019105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05019105, "Phase 1 ALKS 1140 in Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05019105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*